JP2024502178A5 - - Google Patents
Info
- Publication number
- JP2024502178A5 JP2024502178A5 JP2023541702A JP2023541702A JP2024502178A5 JP 2024502178 A5 JP2024502178 A5 JP 2024502178A5 JP 2023541702 A JP2023541702 A JP 2023541702A JP 2023541702 A JP2023541702 A JP 2023541702A JP 2024502178 A5 JP2024502178 A5 JP 2024502178A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- group
- acceptable salt
- compound
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163136782P | 2021-01-13 | 2021-01-13 | |
| US63/136,782 | 2021-01-13 | ||
| US202163262040P | 2021-10-04 | 2021-10-04 | |
| US63/262,040 | 2021-10-04 | ||
| PCT/CA2022/050038 WO2022150911A1 (en) | 2021-01-13 | 2022-01-12 | Pyrazolo[3,4-d]pyrimidin-6-yl-sulfonamide derivatives for the inhibition of sgk-1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024502178A JP2024502178A (ja) | 2024-01-17 |
| JP2024502178A5 true JP2024502178A5 (enExample) | 2025-01-17 |
Family
ID=82446316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023541702A Pending JP2024502178A (ja) | 2021-01-13 | 2022-01-12 | Ｓｇｋ－１を阻害するためのピラゾロ［３，４－ｄ］ピリミジン－６－イル－スルホンアミド誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240309005A1 (enExample) |
| EP (1) | EP4277905A4 (enExample) |
| JP (1) | JP2024502178A (enExample) |
| KR (1) | KR20230136622A (enExample) |
| CN (1) | CN121517419A (enExample) |
| AU (1) | AU2022208639A1 (enExample) |
| MX (1) | MX2023008219A (enExample) |
| WO (1) | WO2022150911A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025525475A (ja) * | 2022-07-12 | 2025-08-05 | スリブ セラピューティクス インコーポレイテッド | Ｎ－［４－（４－［［２－（ジメチルアミノ）エチル］アミノ］－３－メチル－１Ｈ－ピラゾロ［３，４－ｄ］ピリミジン－６－イル）－２－フルオロフェニル］－２，５－ジフルオロベンゼンスルホンアミドの塩及びそれらの結晶形態 |
| WO2024015055A1 (en) * | 2022-07-13 | 2024-01-18 | Thryv Therapeutics Inc. | Pyrazolo[3,4-d]pyrimidin-6-yl-sulfonamide derivatives for the inhibition of sgk-1 and treatment of cancer |
| KR102912267B1 (ko) * | 2023-04-20 | 2026-01-15 | 한국화학연구원 | 신규한 헤테로고리 화합물 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 포함하는 바이러스성 질환의 예방 또는 치료용 약학적 조성물 |
| WO2025072438A1 (en) * | 2023-09-27 | 2025-04-03 | Bristol-Myers Squibb Company | Piperidine substituted pyrazolopyrimidine derivatives as inhibitors of sgk1 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5827849B2 (ja) * | 2011-09-20 | 2015-12-02 | サノフイ | Ｎ−［４−（１Ｈ−ピラゾロ［３，４−ｂ］ピラジン−６−イル）−フェニル］−スルホンアミド及び薬剤としてのその使用 |
| TWI629275B (zh) * | 2013-03-13 | 2018-07-11 | 賽諾菲公司 | Ｎ－（４－（氮雜吲唑－６－基）－苯基）－磺醯胺及其作為醫藥之用途 |
| WO2015048531A1 (en) * | 2013-09-26 | 2015-04-02 | Beth Israel Deaconess Medical Center, Inc. | Inhibition of sgk1 in the treatment of heart conditions |
| AU2017373758B2 (en) * | 2016-12-07 | 2021-12-16 | Orimos Therapeutics Co., Ltd. | Compounds and pharmaceutical compositions for modulating SGK activity, and methods thereof |
-
2022
- 2022-01-12 EP EP22738863.4A patent/EP4277905A4/en active Pending
- 2022-01-12 AU AU2022208639A patent/AU2022208639A1/en active Pending
- 2022-01-12 JP JP2023541702A patent/JP2024502178A/ja active Pending
- 2022-01-12 CN CN202511808384.4A patent/CN121517419A/zh active Pending
- 2022-01-12 KR KR1020237027620A patent/KR20230136622A/ko active Pending
- 2022-01-12 MX MX2023008219A patent/MX2023008219A/es unknown
- 2022-01-12 US US18/272,162 patent/US20240309005A1/en active Pending
- 2022-01-12 WO PCT/CA2022/050038 patent/WO2022150911A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024502178A5 (enExample) | ||
| JP2022121594A5 (enExample) | ||
| JP2019529444A5 (enExample) | ||
| JP2024050527A5 (enExample) | ||
| JP2022533069A5 (enExample) | ||
| JP6087367B2 (ja) | 三環式化合物、それらを含む組成物およびそれらの使用 | |
| JP2022543155A5 (enExample) | ||
| JP2007505933A5 (enExample) | ||
| JP2019530724A5 (enExample) | ||
| JP2007527919A5 (enExample) | ||
| JP2009541225A5 (enExample) | ||
| JP2020111571A5 (enExample) | ||
| JP2015508068A5 (enExample) | ||
| KR20110013411A (ko) | (ｆ-19)-표지된 ｌ-글루탐산 및 ｌ-글루타민 유도체 (ⅲ), 그의 용도 및 그의 수득 방법 | |
| JP2023537271A5 (enExample) | ||
| JP2024545787A5 (enExample) | ||
| JP2023513793A5 (enExample) | ||
| JP2007505044A5 (enExample) | ||
| JP2020511450A5 (enExample) | ||
| JP2023524519A5 (enExample) | ||
| JP2023527961A5 (enExample) | ||
| JP2018502911A5 (enExample) | ||
| FR2967671A1 (fr) | Complexe de technetium 99m en tant qu'outil de diagnostic in vivo des tumeurs cancereuses | |
| JP2022521474A5 (enExample) | ||
| KR101920902B1 (ko) | 심혈관 질환 조기진단 pet 조영용 화합물 및 그의 용도 |